Skip to main content
Top
Published in: Pituitary 4/2014

01-08-2014

Cushing’s disease, pseudo-Cushing states and the dexamethasone test: a historical and critical review

Author: J. Lindholm

Published in: Pituitary | Issue 4/2014

Login to get access

Abstract

The dexamethasone (DXM) test has been widely used for diagnosing Cushing’s disease (CD). The purpose of this paper is to review its diagnostic merit based on calculation of data extracted from earlier publications. Studies presenting individual values for patients with CD and normal subjects were identified through PubMed searches and references in pertinent studies. Calculation of the retrieved data demonstrated huge variation in the relative suppressibility, negative suppression being common. Furthermore, in almost each study retrieved, the pre and post DXM values were closely correlated. Finally, the generally accepted view that DXM causes less suppression in Cushing’s disease than in euadrenal controls appears unfounded. A central issue in the definition of so-called “pseudo-Cushing’s states” is failure to suppress cortisol secretion with DXM. From analysis of the literature it appears quite possible that this does not reflect a specific endocrine deficit, but a physiological “stress” reaction. The above issues question the diagnostic value of the test, in particular in clinically and biochemically borderline cases.
Literature
2.
go back to reference Cushing H (1912) The pituitary body and its disorders, clinical states produced by disorders of the hypophysis cerebri. Lippincott, Philadelphia, pp 1–341 Cushing H (1912) The pituitary body and its disorders, clinical states produced by disorders of the hypophysis cerebri. Lippincott, Philadelphia, pp 1–341
3.
go back to reference Cushing H (1932) The basophilic adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 50:137–195 Cushing H (1932) The basophilic adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 50:137–195
4.
go back to reference Kepler EJ (1949) Cushing’s disease: a primary disorder of the adrenal cortices. Ann NY Acad Sci 50:657–678PubMedCrossRef Kepler EJ (1949) Cushing’s disease: a primary disorder of the adrenal cortices. Ann NY Acad Sci 50:657–678PubMedCrossRef
5.
go back to reference Bauer J (1950) The so-called Cushing’s syndrome, its history, terminology and differential diagnosis. Acta Med Scand 137:411–416PubMedCrossRef Bauer J (1950) The so-called Cushing’s syndrome, its history, terminology and differential diagnosis. Acta Med Scand 137:411–416PubMedCrossRef
6.
go back to reference Norymberski JD, Stubbs RD, West HE (1953) Assessment of adrenocortical activity by assay of 17-ketogenic steroids in urine. Lancet 261:1276–1281CrossRef Norymberski JD, Stubbs RD, West HE (1953) Assessment of adrenocortical activity by assay of 17-ketogenic steroids in urine. Lancet 261:1276–1281CrossRef
7.
go back to reference Porter CC, Silber RH (1950) A quantitative color reaction for cortisone and related 17:21-dihydroxy-20-ketosteroids. J Biol Chem 185:201–207PubMed Porter CC, Silber RH (1950) A quantitative color reaction for cortisone and related 17:21-dihydroxy-20-ketosteroids. J Biol Chem 185:201–207PubMed
8.
go back to reference Schteingart DE, Gregerman RI, Conn JW (1963) A comparison of the characteristics of increased adrenocortical function in obesity and in Cushing’s syndrome. Metabolism 12:484–497PubMed Schteingart DE, Gregerman RI, Conn JW (1963) A comparison of the characteristics of increased adrenocortical function in obesity and in Cushing’s syndrome. Metabolism 12:484–497PubMed
10.
go back to reference Beisel WR, Cos JJ, Horton R, Chao PY, Forsham PH (1964) Physiology of urinary cortisol. J Clin Endocrinol Metabol 24:887–893CrossRef Beisel WR, Cos JJ, Horton R, Chao PY, Forsham PH (1964) Physiology of urinary cortisol. J Clin Endocrinol Metabol 24:887–893CrossRef
11.
go back to reference Lindholm J (1973) The urinary excretion of cortisol. Scand J Lab Clin Invest 31:115–118CrossRef Lindholm J (1973) The urinary excretion of cortisol. Scand J Lab Clin Invest 31:115–118CrossRef
12.
go back to reference Wilkins L, Lewis R, Klein R, Rosenberg E (1950) The suppression of androgen secretion by cortisone in a case of congenital adrenal hyperplasia. Bull Johns Hopkins Hosp 86:249–252PubMed Wilkins L, Lewis R, Klein R, Rosenberg E (1950) The suppression of androgen secretion by cortisone in a case of congenital adrenal hyperplasia. Bull Johns Hopkins Hosp 86:249–252PubMed
13.
go back to reference Jailer JW, Louchart J, Cahill GF (1952) Adrenal virilism. 1 Diagnostic consideration and treatment. JAMA 150:575–579CrossRef Jailer JW, Louchart J, Cahill GF (1952) Adrenal virilism. 1 Diagnostic consideration and treatment. JAMA 150:575–579CrossRef
14.
go back to reference Segaloff A, Gordon D, Horwitt BN (1955) Differential diagnosis of adrenal lesions by the use of intravenous administration of hydrocortisone. J Lab Clin Med 45:219–227PubMed Segaloff A, Gordon D, Horwitt BN (1955) Differential diagnosis of adrenal lesions by the use of intravenous administration of hydrocortisone. J Lab Clin Med 45:219–227PubMed
15.
go back to reference Jailer JW, Louchart JWT, Gold JJ, Knowlton A, Cahill GF (1953) The effect of cortisone on the urinary excretion of 17-ketosteroids in patients with Cushing’s syndrome. J Clin Invest 32:449–451PubMedCentralPubMedCrossRef Jailer JW, Louchart JWT, Gold JJ, Knowlton A, Cahill GF (1953) The effect of cortisone on the urinary excretion of 17-ketosteroids in patients with Cushing’s syndrome. J Clin Invest 32:449–451PubMedCentralPubMedCrossRef
16.
go back to reference Jailer JW, Gold JJ, Wallace EZ (1954) Evaluation of the “cortisone test” as a diagnostic aid in differentiating adrenal hyperplasia from adrenal neoplasia. Am J Med 16:340–345PubMedCrossRef Jailer JW, Gold JJ, Wallace EZ (1954) Evaluation of the “cortisone test” as a diagnostic aid in differentiating adrenal hyperplasia from adrenal neoplasia. Am J Med 16:340–345PubMedCrossRef
18.
go back to reference Liddle GW (1960) Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing’s syndrome. J Clin Endocrinol Metabol 20:1539–1560CrossRef Liddle GW (1960) Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing’s syndrome. J Clin Endocrinol Metabol 20:1539–1560CrossRef
19.
go back to reference Nugent CA, Nichols T, Tayler FH (1965) Diagnosis of Cushing’s syndrome: single dose dexamethasone suppression test. Arch Intern Med 116:172–176PubMedCrossRef Nugent CA, Nichols T, Tayler FH (1965) Diagnosis of Cushing’s syndrome: single dose dexamethasone suppression test. Arch Intern Med 116:172–176PubMedCrossRef
20.
go back to reference Pavlatos FC, Smilo RP, Forsham PH (1965) A rapid screening test for Cushing’s syndrome. JAMA 193:720–723PubMedCrossRef Pavlatos FC, Smilo RP, Forsham PH (1965) A rapid screening test for Cushing’s syndrome. JAMA 193:720–723PubMedCrossRef
21.
go back to reference Kennedy L, Atkinson AB, Johnston H, Sheridan B, Hadden DR (1984) Serum cortisol concentrations during low dose dexamethasone suppression test to screen for Cushing’s syndrome. BMJ (Clin Res Ed) 289:1188–1191CrossRef Kennedy L, Atkinson AB, Johnston H, Sheridan B, Hadden DR (1984) Serum cortisol concentrations during low dose dexamethasone suppression test to screen for Cushing’s syndrome. BMJ (Clin Res Ed) 289:1188–1191CrossRef
22.
go back to reference Odagiri E, Demura R, Demura H, Suda T, Ishiwatari N, Abe Y, Jibiki K, Shizume K (1988) The changes in plasma cortisol and urinary free cortisol by an overnight dexamethasone suppression test in patients with Cushing’s disease. Endocrinol Jpn 35:795–802PubMedCrossRef Odagiri E, Demura R, Demura H, Suda T, Ishiwatari N, Abe Y, Jibiki K, Shizume K (1988) The changes in plasma cortisol and urinary free cortisol by an overnight dexamethasone suppression test in patients with Cushing’s disease. Endocrinol Jpn 35:795–802PubMedCrossRef
23.
go back to reference Barth JH, Seth J, Howlett TA, Freedman DB (1995) A survey of endocrine function testing by clinical biochemistry laboratories in the UK. Ann Clin Biochem 32:442–449PubMedCrossRef Barth JH, Seth J, Howlett TA, Freedman DB (1995) A survey of endocrine function testing by clinical biochemistry laboratories in the UK. Ann Clin Biochem 32:442–449PubMedCrossRef
25.
go back to reference Burke CW, Beardwell CG (1973) Cushing’s syndrome. An evaluation of the clinical usefulness of urinary free cortisol and other urinary steroid measurements in diagnosis. QJM 42:175–204PubMed Burke CW, Beardwell CG (1973) Cushing’s syndrome. An evaluation of the clinical usefulness of urinary free cortisol and other urinary steroid measurements in diagnosis. QJM 42:175–204PubMed
26.
go back to reference Meikle AW (1982) Dexamethasone suppression tests: usefulness of simultaneous measurement of plasma cortisol and dexamethasone. Clin Endocrinol 16:401–408CrossRef Meikle AW (1982) Dexamethasone suppression tests: usefulness of simultaneous measurement of plasma cortisol and dexamethasone. Clin Endocrinol 16:401–408CrossRef
27.
go back to reference Croughs RJ, Docter R, de Jong FH (1973) Comparison of oral and intravenous dexamethasone suppression tests in the differential diagnosis of Cushing’s syndrome. Acta Endocrinol 72:54–62PubMed Croughs RJ, Docter R, de Jong FH (1973) Comparison of oral and intravenous dexamethasone suppression tests in the differential diagnosis of Cushing’s syndrome. Acta Endocrinol 72:54–62PubMed
29.
go back to reference Eddy RL, Jones AL, Gilliland PF, Ibarra JD, Thompson JQ, McMurry JF (1973) Cushing’s syndrome: a prospective study of diagnostic methods. Am J Med 55:621–630PubMedCrossRef Eddy RL, Jones AL, Gilliland PF, Ibarra JD, Thompson JQ, McMurry JF (1973) Cushing’s syndrome: a prospective study of diagnostic methods. Am J Med 55:621–630PubMedCrossRef
30.
go back to reference Tran HA, Petrovsky N (2005) Dexamethasone infusion testing in the diagnosis of Cushing’s syndrome. Endocr J 52:103–109PubMedCrossRef Tran HA, Petrovsky N (2005) Dexamethasone infusion testing in the diagnosis of Cushing’s syndrome. Endocr J 52:103–109PubMedCrossRef
32.
33.
go back to reference Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M (2003) Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 88:5593–5602PubMedCrossRef Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M (2003) Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 88:5593–5602PubMedCrossRef
34.
go back to reference Isidori AM, Kaltsas GA, Mohammed S, Morris DG, Jenkins P, Chew SL, Monson JP, Besser GM, Grossman AB (2003) Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing’s syndrome. J Clin Endocrinol Metabol 88:5299–5306CrossRef Isidori AM, Kaltsas GA, Mohammed S, Morris DG, Jenkins P, Chew SL, Monson JP, Besser GM, Grossman AB (2003) Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing’s syndrome. J Clin Endocrinol Metabol 88:5299–5306CrossRef
35.
go back to reference Newell-Price J, Bertagna X, Grossman AB, Nieman LK (2006) Cushing’s syndrome. Lancet 367:1605–1617PubMedCrossRef Newell-Price J, Bertagna X, Grossman AB, Nieman LK (2006) Cushing’s syndrome. Lancet 367:1605–1617PubMedCrossRef
36.
37.
go back to reference Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM (2008) The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metabol 93:1526–1540CrossRef Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM (2008) The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metabol 93:1526–1540CrossRef
38.
go back to reference Suda T, Kageyama K, Nigawara T, Sakihara S (2009) Evaluation of diagnostic tests for ACTH-dependent Cushing’s syndrome. Endocr J 56:469–476PubMedCrossRef Suda T, Kageyama K, Nigawara T, Sakihara S (2009) Evaluation of diagnostic tests for ACTH-dependent Cushing’s syndrome. Endocr J 56:469–476PubMedCrossRef
39.
go back to reference Branconnier RJ, Oxenkrug GF, McIntyre I, Pomara N, Harto NE, Gershon S (1984) Prediction of serum cortisol response to dexamethasone in normal volunteers: a multivariate approach. Psychopharmacology 84:274–275PubMedCrossRef Branconnier RJ, Oxenkrug GF, McIntyre I, Pomara N, Harto NE, Gershon S (1984) Prediction of serum cortisol response to dexamethasone in normal volunteers: a multivariate approach. Psychopharmacology 84:274–275PubMedCrossRef
40.
go back to reference Lindholm J (1992) Endocrine studies in patients with Cushing’s disease before and after treatment. Clin Endocrinol 36:151–159CrossRef Lindholm J (1992) Endocrine studies in patients with Cushing’s disease before and after treatment. Clin Endocrinol 36:151–159CrossRef
41.
go back to reference Findling JW, Raff H, Aron DC (2004) The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing’s syndrome. J Clin Endocrinol Metabol 89:1222–1226CrossRef Findling JW, Raff H, Aron DC (2004) The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing’s syndrome. J Clin Endocrinol Metabol 89:1222–1226CrossRef
42.
go back to reference Friedman TC (2006) An update on the overnight dexamethasone suppression test for the diagnosis of Cushing’s syndrome: limitations in patients with mild and/or episodic hypercortisolism. Exp Clin Endocrinol Diabetes 114:356–360PubMedCrossRef Friedman TC (2006) An update on the overnight dexamethasone suppression test for the diagnosis of Cushing’s syndrome: limitations in patients with mild and/or episodic hypercortisolism. Exp Clin Endocrinol Diabetes 114:356–360PubMedCrossRef
43.
go back to reference Board F, Wadeson R, Hamburg D (1956) Psychological stress and endocrine functions. Psychosom Med 18:324–333PubMedCrossRef Board F, Wadeson R, Hamburg D (1956) Psychological stress and endocrine functions. Psychosom Med 18:324–333PubMedCrossRef
44.
go back to reference Carroll BJ, Martin FI, Davies B (1968) Resistance to suppression by dexamethasone of plasma 11-OHCS levels in severe depressive illness. BMJ 3:285–287PubMedCentralPubMedCrossRef Carroll BJ, Martin FI, Davies B (1968) Resistance to suppression by dexamethasone of plasma 11-OHCS levels in severe depressive illness. BMJ 3:285–287PubMedCentralPubMedCrossRef
45.
go back to reference Georgotas A, McCue RE, Kim OM, Hapworth WE, Reisberg B, Stoll PM, Sinaiko E, Fanelli C, Stokes PE (1986) Dexamethasone suppressionin dementia, depression, and normal aging. Am J Psychiatry 143:452–456PubMed Georgotas A, McCue RE, Kim OM, Hapworth WE, Reisberg B, Stoll PM, Sinaiko E, Fanelli C, Stokes PE (1986) Dexamethasone suppressionin dementia, depression, and normal aging. Am J Psychiatry 143:452–456PubMed
46.
go back to reference Coppen A, Abou-Saleh M, Milln P, Metcalfe M, Harwood J, Bailey J (1983) Dexamethasone suppression test in depression and other psychiatric illness. Br J Psychiatry 142:498–504PubMedCrossRef Coppen A, Abou-Saleh M, Milln P, Metcalfe M, Harwood J, Bailey J (1983) Dexamethasone suppression test in depression and other psychiatric illness. Br J Psychiatry 142:498–504PubMedCrossRef
47.
go back to reference Gruen PH (1978) Endocrine changes in psychiatric diseases. Med Clin N Am 62:285–295PubMed Gruen PH (1978) Endocrine changes in psychiatric diseases. Med Clin N Am 62:285–295PubMed
48.
go back to reference Brouwer JP, Appelhof BC, Hoogendijk WJ, Huyser J, Endert E, Zuketto C, Schene AH, Tijssen JG, Van Dyck R, Wiersinga WM, Fliers E (2005) Thyroid and adrenal axis in major depression: a controlled study in outpatients. Eur J Endocrinol 152:185–191PubMedCrossRef Brouwer JP, Appelhof BC, Hoogendijk WJ, Huyser J, Endert E, Zuketto C, Schene AH, Tijssen JG, Van Dyck R, Wiersinga WM, Fliers E (2005) Thyroid and adrenal axis in major depression: a controlled study in outpatients. Eur J Endocrinol 152:185–191PubMedCrossRef
49.
go back to reference Rush A, Giles D, Schlesser M, Orsulak P, Weissenburger J, Fulton C, Fairchild C, Roffwarg H (1997) Dexamethasone response, thyrotropin-releasing hormone stimulation, rapid eye movement latency, and subtypes of depression. Biol Psychiatry 41:915–928PubMedCrossRef Rush A, Giles D, Schlesser M, Orsulak P, Weissenburger J, Fulton C, Fairchild C, Roffwarg H (1997) Dexamethasone response, thyrotropin-releasing hormone stimulation, rapid eye movement latency, and subtypes of depression. Biol Psychiatry 41:915–928PubMedCrossRef
50.
go back to reference Hasselbalch H, Selmer J, Sestoft L, Kehlet H (1982) Hypothalamic-pituitary-adrenocortical function in chronic alcoholism. Clin Endocrinol 16:73–76CrossRef Hasselbalch H, Selmer J, Sestoft L, Kehlet H (1982) Hypothalamic-pituitary-adrenocortical function in chronic alcoholism. Clin Endocrinol 16:73–76CrossRef
51.
go back to reference Davis JRE, Jeffcoate WJ (1983) Lack of effect of ethanol on plasma cortisol in man. Clin Endocrinol 19:461–466CrossRef Davis JRE, Jeffcoate WJ (1983) Lack of effect of ethanol on plasma cortisol in man. Clin Endocrinol 19:461–466CrossRef
52.
go back to reference Bishop MC, Ross EJ (1971) Adrenocortical activity in disseminated malignant disease in relation to prognosis. Br J Cancer 25:719–725 Bishop MC, Ross EJ (1971) Adrenocortical activity in disseminated malignant disease in relation to prognosis. Br J Cancer 25:719–725
53.
go back to reference Jenkins PJ, Sohaib SA, Trainer PJ, Lister TA, Besser GM, Reznek R (1999) Adrenal enlargement and failure of suppression of circulating cortisol by dexamethasone in patients with malignancy. Br J Cancer 80:1815–1819PubMedCentralPubMedCrossRef Jenkins PJ, Sohaib SA, Trainer PJ, Lister TA, Besser GM, Reznek R (1999) Adrenal enlargement and failure of suppression of circulating cortisol by dexamethasone in patients with malignancy. Br J Cancer 80:1815–1819PubMedCentralPubMedCrossRef
54.
go back to reference Reincke M, Allolio B, Wurth G, Winkelmann W (1993) The hypothalamic-pituitary-adrenal axis in critical illness: response to dexamethasone and corticotropin-releasing hormone. J Clin Endocrinol Metab 77:151–156PubMed Reincke M, Allolio B, Wurth G, Winkelmann W (1993) The hypothalamic-pituitary-adrenal axis in critical illness: response to dexamethasone and corticotropin-releasing hormone. J Clin Endocrinol Metab 77:151–156PubMed
55.
go back to reference Perrot D, Bonneton A, Dechaud H, Motin J, Pugeat M (1993) Hypercortisolism in septic shock is not suppressible by dexamethasone infusion. Crit Care Med 21:396–401PubMedCrossRef Perrot D, Bonneton A, Dechaud H, Motin J, Pugeat M (1993) Hypercortisolism in septic shock is not suppressible by dexamethasone infusion. Crit Care Med 21:396–401PubMedCrossRef
56.
go back to reference Chiodini I (2011) Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab 96:1223–1236PubMedCrossRef Chiodini I (2011) Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab 96:1223–1236PubMedCrossRef
57.
go back to reference Arnaldi G, Boscaro M (2012) Adrenal incidentaloma. Best Pract Res Clin Endocrinol Metab 26:405–419PubMedCrossRef Arnaldi G, Boscaro M (2012) Adrenal incidentaloma. Best Pract Res Clin Endocrinol Metab 26:405–419PubMedCrossRef
58.
go back to reference Stewart PM (2010) Is subclinical Cushing’s syndrome an entity or a statistical fallout from diagnostic testing? Consensus surrounding the diagnosis is required before optimal treatment can be defined. J Clin Endocrinol Metabol 95:2618–2620CrossRef Stewart PM (2010) Is subclinical Cushing’s syndrome an entity or a statistical fallout from diagnostic testing? Consensus surrounding the diagnosis is required before optimal treatment can be defined. J Clin Endocrinol Metabol 95:2618–2620CrossRef
59.
go back to reference Tyrrell JB, Findling JW, Aron DC, Fitzgerald PA, Forsham PH (1986) An overnight high-dose dexamethasone suppression test for rapid differential diagnosis of Cushing’s syndrome. Ann Intern Med 104:180–186PubMedCrossRef Tyrrell JB, Findling JW, Aron DC, Fitzgerald PA, Forsham PH (1986) An overnight high-dose dexamethasone suppression test for rapid differential diagnosis of Cushing’s syndrome. Ann Intern Med 104:180–186PubMedCrossRef
60.
go back to reference Grossman AB, Howlett TA, Perry L, Coy DH, Savage MO, Lavender P, Rees LH, Besser GM (1988) CRF in the differential diagnosis of Cushing’s syndrome: a comparison with the dexamethasone suppression test. Clin Endocrinol 29:167–178CrossRef Grossman AB, Howlett TA, Perry L, Coy DH, Savage MO, Lavender P, Rees LH, Besser GM (1988) CRF in the differential diagnosis of Cushing’s syndrome: a comparison with the dexamethasone suppression test. Clin Endocrinol 29:167–178CrossRef
61.
go back to reference Blunt SB, Sandler LM, Burrin JM, Joplin GF (1990) An evaluation of the distinction of ectopic and pituitary ACTH dependent Cushing’s syndrome by clinical features: biochemical tests and radiological findings. QJM 77:1113–1133PubMedCrossRef Blunt SB, Sandler LM, Burrin JM, Joplin GF (1990) An evaluation of the distinction of ectopic and pituitary ACTH dependent Cushing’s syndrome by clinical features: biochemical tests and radiological findings. QJM 77:1113–1133PubMedCrossRef
62.
go back to reference Al-Saadi N, Diederich S, Oelkers W (1998) A very high dose dexamethasone suppression test for differential diagnosis of Cushing’s syndrome. Clin Endocrinol 48:45–51CrossRef Al-Saadi N, Diederich S, Oelkers W (1998) A very high dose dexamethasone suppression test for differential diagnosis of Cushing’s syndrome. Clin Endocrinol 48:45–51CrossRef
63.
go back to reference Lindholm J, Juul S, Jørgensen JOL, Astrup J, Bjerre P, Hagen C, Jørgensen J, Kosteljanetz M, Kristensen LØ, Laurberg P, Feldt-Rasmussen U, Schmidt K, Weeke J (2001) Incidence and late prognosis of Cushing’s syndrome: a population based study. J Clin Endocrinol Metabol 86:117–123 Lindholm J, Juul S, Jørgensen JOL, Astrup J, Bjerre P, Hagen C, Jørgensen J, Kosteljanetz M, Kristensen LØ, Laurberg P, Feldt-Rasmussen U, Schmidt K, Weeke J (2001) Incidence and late prognosis of Cushing’s syndrome: a population based study. J Clin Endocrinol Metabol 86:117–123
Metadata
Title
Cushing’s disease, pseudo-Cushing states and the dexamethasone test: a historical and critical review
Author
J. Lindholm
Publication date
01-08-2014
Publisher
Springer US
Published in
Pituitary / Issue 4/2014
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-013-0509-x

Other articles of this Issue 4/2014

Pituitary 4/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.